leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...123124125126127128129130131132133...235236»
  • ||||||||||  methotrexate / Generic mfg.
    Clinical, Review, Journal, Adverse events:  Methotrexate-Induced Cutaneous Ulcers: A Rare Side Effect. (Pubmed Central) -  Sep 3, 2021   
    Within a couple weeks of methotrexate discontinuation, the ulcers resolved. Our case in addition to a review of the literature suggests that methotrexate-induced cutaneous ulceration may be an indication of life-threatening pancytopenia.
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    Journal:  Role of folinic acid in methotrexate-based prophylaxis of graft-versus-host disease following hematopoietic stem cell transplantation. (Pubmed Central) -  Sep 3, 2021   
    I discuss the available literature and evaluate the evidence for the effect of FA on MTX toxicity and its safety regarding GvHD development and graft rejection in both adult and pediatric patients. Although FA administration appears to be safe, its efficacy for routine use in all types of transplants in adult patients is unproven and further research is required to confirm its MTX toxicity-lowering effect, identify the individual parameters that influence its usefulness in clinical practice, and evaluate its potential when developing a personalized prophylaxis regimen.
  • ||||||||||  Trial completion date, Trial primary completion date:  A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Sep 2, 2021   
    P2,  N=39, Active, not recruiting, 
    Although FA administration appears to be safe, its efficacy for routine use in all types of transplants in adult patients is unproven and further research is required to confirm its MTX toxicity-lowering effect, identify the individual parameters that influence its usefulness in clinical practice, and evaluate its potential when developing a personalized prophylaxis regimen. Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Aug 2022
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    New P2/3 trial, Metastases:  ALIVE: Immunotherapy for Advanced Liver Cancer (clinicaltrials.gov) -  Sep 1, 2021   
    P2/3,  N=150, Not yet recruiting, 
  • ||||||||||  cisplatin / Generic mfg.
    Clinical, Clinical guideline, Journal:  SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). (Pubmed Central) -  Sep 1, 2021   
    In metastatic BTC, cisplatin plus gemcitabine constitute the standard treatment. Progress in the knowledge of molecular biology has enabled the identification of new targets for therapy with encouraging results that could in the future improve the survival and quality of life of patients with PC and BTC.
  • ||||||||||  Trial initiation date:  Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer (clinicaltrials.gov) -  Sep 1, 2021   
    P1/2,  N=120, Not yet recruiting, 
    Progress in the knowledge of molecular biology has enabled the identification of new targets for therapy with encouraging results that could in the future improve the survival and quality of life of patients with PC and BTC. Initiation date: Jun 2021 --> Oct 2021
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Journal, PD(L)-1 Biomarker, IO biomarker:  Changes in the therapeutic landscape of oesophago-gastric cancers. (Pubmed Central) -  Aug 29, 2021   
    Chemo-immunotherapy combinations will become the new standard of care for some patients with metastatic oesophago-gastric cancers. Adjuvant nivolumab is a new option for oesophageal cancer patients with poor response after neoadjuvant chemoradiation.
  • ||||||||||  leucovorin calcium / Generic mfg.
    Review, Journal:  Folate Receptor Alpha Autoantibodies in Autism Spectrum Disorders: Diagnosis, Treatment and Prevention. (Pubmed Central) -  Aug 28, 2021   
    Autoantibodies against folate receptor alpha (FRα) are present in about 70% of the children with a diagnosis of ASD, and a significant number of these children respond to oral folinic acid with overall improvements in speech, language and social interaction. The diagnosis of folate receptor autoimmune disorder by measuring autoantibodies against FRα in the serum provides a marker with the potential for treatment and perhaps preventing the pathologic consequences of folate receptor autoimmune disorder.
  • ||||||||||  Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Retrospective data, Journal:  Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. (Pubmed Central) -  Aug 28, 2021   
    The diagnosis of folate receptor autoimmune disorder by measuring autoantibodies against FRα in the serum provides a marker with the potential for treatment and perhaps preventing the pathologic consequences of folate receptor autoimmune disorder. Representing one of the largest studies published so far, our results reveal that patients with BRPC/LAPC should be offered either FFX or GNP to improve chances of resection and with this also survival.
  • ||||||||||  Bavencio (avelumab) / EMD Serono
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 (clinicaltrials.gov) -  Aug 27, 2021   
    P2,  N=30, Completed, 
    NIVO + chemo continued to demonstrate clinically meaningful long-term survival benefit vs chemo and an acceptable safety profile with additional follow-up, further supporting its use as a new standard 1L treatment in pts with advanced GC/GEJC/EAC. Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Aug 2021 | Trial primary completion date: Aug 2022 --> Aug 2021
  • ||||||||||  Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Clinical, Review, Journal:  Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer? (Pubmed Central) -  Aug 27, 2021   
    Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Aug 2021 | Trial primary completion date: Aug 2022 --> Aug 2021 No abstract available
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Modified FOLFIRINOX for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen. (Pubmed Central) -  Aug 26, 2021   
    The first-line chemotherapy regimen for advanced gallbladder cancer (GBC) is gemcitabine plus platinum (GP), despite its efficacy is limited...The incidence of grade 3-4 neutropenia and diarrhea were more common in the mFOLFIRINOX group, while the incidence of grade 3-4 thrombocytopenia and peripheral neuropathy were more common in the GEMOX group. mFOLFIRINOX might improve the poor prognosis of unresectable locally advanced or metastatic GBC, and the results need to be further verified by prospective clinical studies.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Supportive oncology care at home intervention for patients with pancreatic cancer. () -  Aug 26, 2021 - Abstract #ASCOQC2021ASCO_QC_409;    
    These findings demonstrate the feasibility and acceptability of a Supportive Oncology Care at Home intervention. Future work will investigate the efficacy of this intervention for decreasing healthcare use and improving patient outcomes.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
    Sustainability and clinical outcomes of routine screening for pathogenic DPYD gene variants prior to fluoropyrimidine (FP) chemotherapy for gastrointestinal (GI) cancer. () -  Aug 26, 2021 - Abstract #ASCOQC2021ASCO_QC_267;    
    Following a sentinel toxicity event the GI medical oncology group at the Norris Cotton Cancer Center adopted a shared practice of routine screening for pathogenic DPYD gene variants prior to FP chemotherapy (5-FU or capecitabine)... Routine screening for pathogenic DPYD gene variants prior to FP chemotherapy is feasible and sustainable in the U.S. DPYD genotyping coupled with chemotherapy dose reductions for DPYD variant carriers facilitates safe and timely completion of planned chemotherapy treatments.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Supportive oncology care at home intervention for patients with pancreatic cancer. () -  Aug 26, 2021 - Abstract #ASCOQC2021ASCO_QC_230;    
    These findings demonstrate the feasibility and acceptability of a Supportive Oncology Care at Home intervention. Future work will investigate the efficacy of this intervention for decreasing healthcare use and improving patient outcomes.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Racial disparities in comprehensive biomarker testing and clinical trial enrollment among patients with metastatic colorectal cancer (mCRC). () -  Aug 26, 2021 - Abstract #ASCOQC2021ASCO_QC_142;    
    The significant relationship between NGS testing and clinical trial enrollment at any time in the database did not appear to be moderated by race; however, descriptive analyses suggest that the ongoing analyses by line of therapy and considering timing of testing may better quantify these relationships. These data may not be generalizable to the entire US population as they are obtained from a single database that is limited to practices using this EHR system.
  • ||||||||||  methotrexate / Generic mfg.
    Can high-dose methotrexate be safely administered to outpatients? () -  Aug 26, 2021 - Abstract #ASCOQC2021ASCO_QC_59;    
    Leucovorin and continuous intravenous hydration were administered via ambulatory infusion pumps. Outpatient administration of HD-MTX can be administered safely and effectively as CNS prophylaxis in select patients with DLBCL.
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly
    Trial primary completion date, Combination therapy:  FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (clinicaltrials.gov) -  Aug 26, 2021   
    P2/3,  N=180, Active, not recruiting, 
    Outpatient administration of HD-MTX can be administered safely and effectively as CNS prophylaxis in select patients with DLBCL. Trial primary completion date: Apr 2021 --> Sep 2021
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    [VIRTUAL] A BIZZARE CASE OF ECTOPIC MOLAR PREGNANCY IN BROAD LIGAMENT PROGRESSING TO GTN () -  Aug 26, 2021 - Abstract #IGCS2021IGCS_771;    
    Because of high initial beta HCG levels, large size of ectopic molar mass and fear of losing the patient to follow-up, prophylactic chemotherapy with single agent methotrexate 50 mg alternating with folinic acid was started. This bizzare case clearly substantiates the existence of such rare conditions and also reinforces the importance of follow-up.